CLINICAL TRIAL EVIDENCE FOR GLP-1 RAs IN MASH Table 2 provides a summary of phase 2 and phase 3 studies examining GLP-1 RAs and dual or triple agonists (aiming glucagon, GIP, and GLP-1 receptors) in individuals with MASLD/MASH, where hepatic biopsies were used to evaluate liver outcomes [3,5,10,11,15,22-25,44-52]
Determining the Best Medication for You Now that you understand how these medications work, we determine which medication is right for you based on your weight loss target
Tang X, Wu J, Ding CK, Lu M, Keenan MM, Lin CC, et al
For a full breakdown of the mechanism and how we structure the protocol, see our clinical guide to what MOTS-c is and how it works as a mitochondrial-derived peptide
This regulation restores the delicate neurotransmitter balance required for clear executive function, focus, and emotional stability
468,469 Moreover, therapeutic interventions targeting metabolic pathways, oxidative stress, and inflammation are being explored to prevent or slow the progression of CAN